Paradigm Genetics gets funds for liver marker work:
This article was originally published in Clinica
Paradigm Genetics has received a $742,000 award in the US to find biochemicals in urine, serum and liver tissue that predict the early onset of drug-induced liver injury. Biomarkers discovered by the firm could provide diagnostics that help pharmaceutical companies better assess drug candidate safety and that might also enable physicians to more effectively diagnose and treat disease. Under the award, from the National Institutes of Health, Paradigm will conduct preclinical studies on three compounds known to cause liver damage, using mass spectrometry to measure changes in hundreds of small molecular weight biochemicals that may be linked to liver toxicity.